Nexavar gets Priority Review for thyroid cancer

FDA accepted and granted Priority Review to an sNDA from Bayer AG (Xetra:BAYN) for Nexavar sorafenib to treat locally advanced or metastatic, radioactive iodine-refractory, differentiated thyroid cancer. The PDUFA date is Dec. 25. Bayer and partner Onyx Pharmaceuticals Inc. (NASDAQ:ONXX) are co-developing Nexavar worldwide. The drug is already approved in more than 100 countries to treat liver cancer and advanced kidney cancer. ...